**DOSING GUIDE**

**JARDIANCE®**

Please refer to the Product Monograph at www.JardiancePM.ca for contraindications, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use. The Product Monograph is also available by calling 1-800-263-5103 ext. 84633.

**SYNJARDY®**

Please refer to the Product Monograph at www.SynjardyPM.ca for contraindications, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use. The Product Monograph is also available by calling 1-800-263-5103 ext. 84633.

**References:**
1. JARDIANCE® Product Monograph, Boehringer Ingelheim (Canada) Ltd., April 15, 2020.

**JARDIANCE®**

**Monotherapy:** JARDIANCE® (empagliflozin) is indicated for use as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus for whom metformin is inappropriate due to contraindications or intolerance.

**Add-on combination:** JARDIANCE® is indicated in adult patients with type 2 diabetes mellitus to improve glycemic control, when metformin used alone does not provide adequate glycemic control, in combination with: metformin, metformin and a sulfonylurea, pioglitazone (alone or with metformin), linagliptin and metformin, basal or prandial insulin (alone or with metformin), when the existing therapy, along with diet and exercise, does not provide adequate glycemic control.

**Add-on combination in patients with established cardiovascular disease:** JARDIANCE® is indicated as an adjunct to diet, exercise and standard care therapy to reduce the incidence of cardiovascular death in patients with type 2 diabetes mellitus and established cardiovascular disease.

**Important limitation of use:** Use of JARDIANCE® with insulin mix (regular or analogue mix) has not been studied. Therefore, JARDIANCE® should not be used with insulin mix.

**SYNJARDY®**

SYNJARDY® (empagliflozin and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus inadequately controlled on:
- metformin
- sulfonylurea in combination with metformin
- pioglitazone in combination with metformin
- insulin in combination with metformin

Or in patients already being treated and achieving glycemic control with:
- metformin and empagliflozin as separate tablets
- sulfonylurea in combination with metformin and empagliflozin as separate tablets
- pioglitazone in combination with metformin and empagliflozin as separate tablets
- insulin in combination with metformin and empagliflozin as separate tablets
JARDIANCE® offers convenient, once-daily oral dosing

JARDIANCE® Dosing

**Recommended starting dose**

10 mg OD

Increase to

25 mg OD

In patients tolerating JARDIANCE® 10 mg OD and requiring additional glycemic control

With or without food, at any time of the day

Renal impairment

The glucose-lowering efficacy of JARDIANCE® declines with decreasing renal function.

- Contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), end-stage renal disease or patients on dialysis
- No dosage adjustment necessary in patients with mild to moderate renal impairment
- More intensive monitoring of glycemic and renal biomarkers and signs and symptoms of renal dysfunction in patients with eGFR <60 mL/min/1.73 m² (especially if eGFR <45 mL/min/1.73 m²)
- Discontinue if eGFR falls to a level persistently <30 mL/min/1.73 m²

Hepatic impairment

- No dosage adjustment needed for patients with mild/moderate hepatic impairment
- Not recommended for use in patients with severe hepatic impairment

General dosing considerations

- Use with caution in patients taking diuretics, particularly loop diuretics
- No dosage adjustment required based on age (however, renal function and risk of volume depletion should be taken into account)
- When JARDIANCE® is added to a sulfonylurea or insulin, a lower dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia

Please see Product Monograph for complete dosing and administration information.

SYNJARDY® contains empagliflozin and metformin in a single tablet

AVAILABLE SYNJARDY® DOSES

2x daily empagliflozin/metformin

<table>
<thead>
<tr>
<th>5/500 mg</th>
<th>5/850 mg</th>
<th>5/1000 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.5/500 mg</td>
<td>12.5/850 mg</td>
<td>12.5/1000 mg</td>
</tr>
</tbody>
</table>

Patients switching from separate tablets of empagliflozin (10 mg or 25 mg total daily dose) and metformin to SYNJARDY® should receive the same daily dose of empagliflozin and metformin already being taken or the nearest therapeutically appropriate dose of metformin.

The maximum recommended daily dose is 25/2000 mg.

**With meals, twice daily**

The dosage should be individualized on the basis of the patient’s current regimen, effectiveness, and tolerability, while not exceeding the recommended daily dose.

Please see Product Monograph for complete dosing and administration information.
**JARDIANCE® offers convenient, once-daily oral dosing**

**JARDIANCE® DOSING**

- **Recommended starting dose**: 10 mg OD
- **Increase to**: 25 mg OD

In patients tolerating JARDIANCE® 10 mg OD and requiring additional glycemic control

With or without food, at any time of the day

**Renal impairment**
- The glucose-lowering efficacy of JARDIANCE® declines with decreasing renal function.
- Contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), end-stage renal disease or patients on dialysis.
- No dosage adjustment necessary in patients with mild to moderate renal impairment.
- More intensive monitoring of glycemic and renal biomarkers and signs and symptoms of renal dysfunction in patients with eGFR <60 mL/min/1.73 m² (especially if eGFR <45 mL/min/1.73 m²).
- Discontinue if eGFR falls to a level persistently <30 mL/min/1.73 m².

**Hepatic impairment**
- No dosage adjustment needed for patients with mild/moderate hepatic impairment.
- Not recommended for use in patients with severe hepatic impairment.

**General dosing considerations**
- Use with caution in patients taking diuretics, particularly loop diuretics.
- No dosage adjustment required based on age (however, renal function and risk of volume depletion should be taken into account).
- When JARDIANCE® is added to a sulfonylurea or insulin, a lower dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia.

Please see Product Monograph for complete dosing and administration information.

**SYNJARDY® contains empagliflozin and metformin in a single tablet**

**AVAILABLE SYNJARDY® DOSES**

- 2x daily empagliflozin/metformin

<table>
<thead>
<tr>
<th>Available Doses</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>5/500 mg</td>
<td>5/500 mg</td>
</tr>
<tr>
<td>5/850 mg</td>
<td>5/850 mg</td>
</tr>
<tr>
<td>5/1000 mg</td>
<td>5/1000 mg</td>
</tr>
<tr>
<td>12.5/500 mg</td>
<td>12.5/500 mg</td>
</tr>
<tr>
<td>12.5/850 mg</td>
<td>12.5/850 mg</td>
</tr>
<tr>
<td>12.5/1000 mg</td>
<td>12.5/1000 mg</td>
</tr>
</tbody>
</table>

 Patients switching from separate tablets of empagliflozin (10 mg or 25 mg total daily dose) and metformin to SYNJARDY® should receive the same daily dose of empagliflozin and metformin already being taken or the nearest therapeutically appropriate dose of metformin.

The maximum recommended daily dose is 25/2000 mg.

**With meals, twice daily**

The dosage should be individualized on the basis of the patient’s current regimen, effectiveness, and tolerability, while not exceeding the recommended daily dose.

Please see Product Monograph for complete dosing and administration information.
**DOSING GUIDE**

**JARDIANCE®**

Please refer to the Product Monograph at www.JardiancePM.ca for contraindications, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use. The Product Monograph is also available by calling 1-800-263-5103 ext. 84633.

**SYNJARDY®**

Please refer to the Product Monograph at www.SynjardyPM.ca for contraindications, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use. The Product Monograph is also available by calling 1-800-263-5103 ext. 84633.

**References:**
1. JARDIANCE® Product Monograph, Boehringer Ingelheim (Canada) Ltd., April 15, 2020.

**JARDIANCE®**

**Monotherapy:** JARDIANCE® (empagliflozin) is indicated for use as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus for whom metformin is inappropriate due to contraindications or intolerance.

**Add-on combination:** JARDIANCE® is indicated in adult patients with type 2 diabetes mellitus to improve glycemic control, when metformin used alone does not provide adequate glycemic control, in combination with: metformin, metformin and a sulfonylurea, pioglitazone (alone or with metformin), linagliptin and metformin, basal or prandial insulin (alone or with metformin), when the existing therapy, along with diet and exercise, does not provide adequate glycemic control.

**Add-on combination in patients with established cardiovascular disease:** JARDIANCE® is indicated as an adjunct to diet, exercise and standard care therapy to reduce the incidence of cardiovascular death in patients with type 2 diabetes mellitus and established cardiovascular disease.

**Important limitation of use:** Use of JARDIANCE® with insulin mix (regular or analogue mix) has not been studied. Therefore, JARDIANCE® should not be used with insulin mix.

**SYNJARDY®**

SYNJARYD® (empagliflozin and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus inadequately controlled on:
• metformin
• sulfonylurea in combination with metformin
• pioglitazone in combination with metformin
• insulin in combination with metformin

Or in patients already being treated and achieving glycemic control with:
• metformin and empagliflozin as separate tablets
• sulfonylurea in combination with metformin and empagliflozin as separate tablets
• pioglitazone in combination with metformin and empagliflozin as separate tablets
• insulin in combination with metformin and empagliflozin as separate tablets